Tentarix Biotherapeutics Launches with a $50 Million Series A Financing

Vancouver BC – August 24, 2020 – Tentarix was launched with a $50 Million Series A Financing and will leverage the ITS HuTARG core protein engineering platform to create multispecific binding molecules based on fully human antibody variable domains (Vds). Tentarix’s mission is to develop first-in-class multispecific therapies. The Company is focused on modalities that have tissue specific function and is building a team that aims to transform biologics.